Skip to main content
PRTA logo

PRTA

Prothena Corp Public Ltd Co
$9.68 +0.18 (+1.89%) At close · Jul 7
Market Cap
$510.44M
Shares
52,353,237

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$9.68 Open$9.62 Day$9.33–9.78 52W$6.16–11.80 Avg vol 30d586K Short int7.9M · 15.0% float · 16.0d Short vol55% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 7
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Neutral
50 / 200-day cross Death cross
Price vs 200-day avg −0%
below
Price vs 50-day avg +0%
above
RSI (14) 55
neutral
MACD trend Positive
52-week position 62%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +10%
trailing
6-month return +9%
trailing
YTD return +1%
this year
Relative strength +1%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) Death cross
50d $10 › 200d $10 — 200d above 50d
Institutional flow Distributing
6 of 185 funds reported for Jun 30 · net -11.5K sh shares
Insider flow Accumulating
Net +$3.1M over 90 days · 0% sells
Short interest Rising
15.03% of float · ▲ +1.7% MoM · 16.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
185 holders — mid 3-yr range
Squeeze score 83
high risk · 0–100
Fundamentals
Strong
Revenue growth +297%
Y/Y
EPS growth −100%
Y/Y
Buyback $100.0M
authorized
Balance sheet $307.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 49%
annualized · 1-yr
Max drawdown −31%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Aug 6, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 7, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      Death cross Bearish
      Price vs 200-day avg
      −0% Neutral
      Price vs 50-day avg
      +0% Bullish
      RSI (14)
      55 Neutral
      MACD trend
      Positive Bullish
      52-week position
      62% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) Death cross
      50d $10 › 200d $10 — 200d above 50d
      Institutional flow Distributing
      6 of 185 funds reported for Jun 30 · net -11.5K sh shares
      Insider flow Accumulating
      Net +$3.1M over 90 days · 0% sells
      Short interest Rising
      15.03% of float · ▲ +1.7% MoM · 16.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      185 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $6 Now $10 · 62% 52-wk high $12
      vs 200-day avg 0% vs 50-day avg +0% 50-day below 200-day death cross

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PRTA
      Prothena Corp Public Ltd Co
      this stock
      $510.44M +1.4% +2508.4% 15.0%
      ONC
      BeOne Medicines Ltd.
      $446.53B +1.7% +22179.2% 908.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $132.55B +15.2% +46.2% 31.0 1.8%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $70.90B -12.3% +20.8% 16.5 3.2%
      ARGX
      Argenx SE
      $57.49B +9.4% 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      185
      % held
      87.9%
      Reported
      6 of 185
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      53
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      7.9M
      Days to cover
      16.0d
      Change
      +129.0K sh
      View
      Short Volume
      Short vol %
      55%
      As of
      Jul 8, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      339
      Value
      $2.7K
      As of
      Jun 11, 2026
      View
      Off-Exchange
      Off-exchange %
      31.3%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$3.1M
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $9.7M
      Net income (FY)
      $-244.1M
      EPS diluted
      $-4.53
      View
      Buybacks
      Authorized
      $100.0M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      May 15, 2026
      This year
      8
      View
      Proposed Sales
      Value
      $740.0K
      Shares
      80.0K
      Filed
      Jun 9, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 7, 2026
      View
      Investor Relations
      Latest news
      Prothena Reports First Quarter 20…
      Published
      May 7, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PRTA -2.9% +10.1% +8.6% -1.1% +1.4%
      SPY +0.9% +1.4% +7.6% +0.1% +9.7%
      vs SPY -3.8% +8.8% +1.1% -1.3% -8.3%

      Capital returns

      Buyback program · as of Feb 27, 2026
      Authorized
      $100.00M
      Spent (derived)
      Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1559053 CUSIP G72800108 13F (30d) 8 filings 7 filers Visit website Investor relations